Results 91 to 100 of about 21,988 (154)

Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis. [PDF]

Curr Issues Mol Biol
Perković D, Petrić M, Maleš M, Erceg Maleš I, Radić M.   +4 more
europepmc   +1 more source

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial [PDF]

, 2010
Vappu Rantalaiho, Markku Korpela, Leena Laasonen, Hannu Kautiainen, Salme Järvenpää, Pekka Hannonen, Marjatta Leirisalo‐Repo, Harri Blåfield, Kari Puolakka, Anna Karjalainen, Timo Möttönen   +10 more
openalex   +1 more source

Correlation of Hematological Indices and Acute-Phase Reactants in Rheumatoid Arthritis Patients on Disease-Modifying Antirheumatic Drugs: A Retrospective Cohort Analysis. [PDF]

J Clin Med, 2023
Pan YJ, Su KY, Shen CL, Wu YF.
europepmc   +1 more source

Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs [PDF]

, 2011
Vivian P. Bykerk, Pooneh Akhavan, Glen Hazlewood, Orit Schieir, Anne Dooley, Boulos Haraoui, Majed Khraishi, Sharon LeClercq, Jean Légaré, DIANE P. MOSHER, James Pencharz, Janet Pope, John Thomson, Carter Thorne, Michel Zummer, Claire Bombardier   +15 more
openalex   +1 more source

Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source

The Examination of the Escape Phenomenon of the Disease Modifying Antirheumatic Drugs

, 2005
Yoichi Kawasaki, Masahiro Moriyama, Kazuhiko Shibata, Yutaka Gomita   +3 more
openalex   +2 more sources

Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature [PDF]

, 2011
Maurizio Benucci, Gianantonio Saviola, Mariangela Manfredi, Piercarlo Sarzi‐Puttini, Fabiola Atzeni   +4 more
openalex   +1 more source

Long-Standing Untreated or Inadequately Treated Seropositive Rheumatoid Arthritis in the Golden Age of Disease-Modifying Antirheumatic Drugs. [PDF]

Cureus
Arcilla CK, Kaeley GS, Thway M.
europepmc   +1 more source

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. [PDF]

Korean J Intern Med, 2023
Cho SK, Kim H, Song YJ, Kim HW, Nam E, Lee SS, Lee HS, Park SH, Lee YA, Park MC, Chang SH, Kim HA, Kwok SK, Kim HR, Kim HS, Yoon BY, Uhm WS, Kim YG, Kim JH, Lee J, Choi J, Sung YK.   +21 more
europepmc   +1 more source

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network. [PDF]

Front Pharmacol
Vitale A, Leone F, Caggiano V, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Ayumi Kawakami-Campos P, Hissaria P, Callisto A, Beecher M, Dagna L, Tomelleri A, Campochiaro C, Frassi M, Crisafulli F, Franceschini F, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Sfriso P, Bindoli S, Baggio C, Sbalchiero J, Sota J, Tufan A, Vasi I, Piga M, Cauli A, D'Agostino MA, De Paulis A, Mormile I, Mayrink Giardini HA, Cordeiro RA, Gavioli F, Lopalco G, Iannone F, Montecucco C, Monti S, Ruiz-Irastorza G, Soto-Peleteiro A, Triggianese P, Gurnari C, Viapiana O, Bixio R, Vitetta R, Conticini E, La Torre F, Ragab G, Batu ED, González-García A, Peña-Rodríguez M, Bocchia M, Wiesik-Szewczyk E, Jahnz-Rózyk K, de-la-Torre A, Balistreri A, Frediani B, Fabiani C, Cantarini L.   +59 more
europepmc   +1 more source